Published in J Urol on June 01, 1983
Clusterin as a possible predictor for biochemical recurrence of prostate cancer following radical prostatectomy with intermediate Gleason scores: a preliminary report. Prostate Cancer Prostatic Dis (2004) 0.83
Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med (2001) 11.73
Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials (2000) 10.99
Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med (1998) 6.84
Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med (1999) 6.21
Quality of life in advanced prostate cancer: results of a randomized therapeutic trial. J Natl Cancer Inst (1998) 3.08
A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol (1992) 2.90
A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. N Engl J Med (1991) 2.07
Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract (2011) 1.75
Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol (1997) 1.70
Complications of cryosurgical ablation of the prostate to treat localized adenocarcinoma of the prostate. Urology (1995) 1.69
Proposed substages for metastatic prostate cancer. Urology (1997) 1.45
The use of flutamide as a single antiandrogen treatment for hormone-refractory prostate cancer. BJU Int (2003) 1.39
Cisplatin, methotrexate and bleomycin for the treatment of carcinoma of the penis: a Southwest Oncology Group study. J Urol (1999) 1.39
The "nutcracker" phenomenon: an unusual cause for renal varicosities with hematuria. J Urol (1980) 1.38
A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Urology (1995) 1.38
A randomized trial of cisplatin, vinblastine, and bleomycin versus vinblastine, cisplatin, and etoposide in the treatment of advanced germ cell tumors of the testis: a Southwest Oncology Group study. J Clin Oncol (1991) 1.38
Androgen deprivation therapy: past, present and future. BJU Int (2012) 1.26
Age- and race-specific reference ranges for prostate-specific antigen from a large community-based study. Urology (1996) 1.24
Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol (1991) 1.22
Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J Urol (1993) 1.18
Current management of invasive and metastatic transitional cell carcinoma of the bladder. J Urol (1993) 1.17
Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report. J Clin Oncol (1994) 1.16
Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: a Southwest Oncology Group Study. J Urol (2001) 1.13
Benign prostatic hyperplasia: an overview. Urology (1999) 1.06
Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review. Urology (2001) 1.06
Genetic variation in the vitamin d pathway in relation to risk of prostate cancer--results from the breast and prostate cancer cohort consortium. Cancer Epidemiol Biomarkers Prev (2013) 1.03
Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. Urology (1996) 1.01
cis-Diamminedichloroplatinum in the treatment of advanced epidermoid carcinoma of the penis: a Southwest Oncology Group Study. J Urol (1989) 1.00
Optimal hormonal therapy for advanced prostatic carcinoma. Semin Oncol (1999) 1.00
A 3-D reconstruction algorithm for interpolation and extrapolation of planar cross sectional data. IEEE Trans Med Imaging (1995) 1.00
Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review. Int J Impot Res (2008) 0.99
Transurethral ultrasound-guided laser-induced prostatectomy: National Human Cooperative Study results. J Urol (1993) 0.98
Estrogens in the treatment of prostate cancer. J Urol (1995) 0.97
New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists. Prostate Cancer Prostatic Dis (2012) 0.96
Metastatic extramammary Paget's disease: dramatic response to combined modality treatment. J Surg Oncol (1988) 0.96
Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal cell carcinoma. A Southwest Oncology Group Study. Cancer (1994) 0.94
Terazosin, doxazosin, and prazosin: current clinical experience. Urology (2001) 0.92
Combined versus sequential chemo-endocrine therapy in advanced prostate cancer: final results of a randomized Southwest Oncology Group study. J Clin Oncol (1990) 0.92
Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235). Urology (2001) 0.92
Adaptation of a 3D prostate cancer atlas for transrectal ultrasound guided target-specific biopsy. Phys Med Biol (2008) 0.92
Prevention of urinary tract infection and sepsis following transrectal prostatic biopsy. J Urol (1982) 0.92
Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers? Cancer (1996) 0.92
Complications of intravesical chemotherapy. Urol Clin North Am (1992) 0.92
Lymphomatoid tumor infiltration of renal veins. J Urol (1979) 0.91
Correlation between LUTS (AUA-SS) and erectile dysfunction (SHIM) in an age-matched racially diverse male population: data from the Prostate Cancer Awareness Week (PCAW). Int J Impot Res (2005) 0.91
Prognostic factors in stage D2 prostate cancer; important implications for future trials: results of a cooperative intergroup study (INT.0036). The National Cancer Institute Intergroup Study #0036. Semin Oncol (1994) 0.91
Phase II evaluation of coumarin (1,2-benzopyrone) in metastatic prostatic carcinoma. Prostate (1992) 0.91
Comparison of telomerase activity and GSTP1 promoter methylation in ejaculate as potential screening tests for prostate cancer. Mol Cell Probes (2000) 0.91
Alternating combination chemotherapy in patients with extragonadal germ cell tumors. A Southwest Oncology Group study. Cancer (1993) 0.91
Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point. J Clin Oncol (2000) 0.90
Clinical staging of prostate cancer: reproducibility and clarification of issues. Int J Cancer (2001) 0.90
Relationship of demographic and clinical factors to free and total prostate-specific antigen. Urology (2001) 0.89
Treatment with gallium nitrate: evidence for interference with iron metabolism in vivo. Am J Hematol (1992) 0.88
Endocrine therapy of advanced carcinoma of the prostate. Cancer (1993) 0.88
Management and challenges of corticosteroid therapy in men with metastatic castrate-resistant prostate cancer. Ann Oncol (2012) 0.88
On the importance of clinical trials. J Urol (1990) 0.87
Complications of radical cystectomy for carcinoma of the bladder. J Urol (1980) 0.87
Computer simulation of the probability of detecting low volume carcinoma of the prostate with six random systematic core biopsies. Urology (1995) 0.86
Treatment of advanced transitional cell carcinoma of the bladder with continuous-infusion gallium nitrate. J Natl Cancer Inst (1991) 0.86
A trial of bacillus Calmette-Guérin versus adriamycin in superficial bladder cancer: a South-West Oncology Group Study. Urol Int (1986) 0.86
Combined androgen blockade for advanced prostatic carcinoma. Prostate Cancer Prostatic Dis (1999) 0.86
Late development of a urethrocavernous fistula after cavernospongiosum shunt for priapism. J Urol (1984) 0.86
Fatal sepsis following intravesical bacillus Calmette-Guerin administration for bladder cancer. J Urol (1990) 0.86
Phase 1 trial of oral bropirimine in superficial bladder cancer. J Urol (1992) 0.85
The effect of ejaculation on prostate-specific antigen in a prostate cancer-screening population. Urology (1998) 0.85
Salvage cystectomy after irradiation failure. J Urol (1980) 0.85
Treatment of advanced bladder cancer with combined preoperative irradiation and radical cystectomy versus radical cystectomy alone: a phase III intergroup study. J Urol (1997) 0.85
Artificial neural network model for the assessment of lymph node spread in patients with clinically localized prostate cancer. Urology (2001) 0.84
Testosterone replacement therapy and the risk of prostate cancer. Is there a link? Int J Impot Res (2005) 0.83
Local toxicity patterns associated with intravesical bacillus Calmette-Guérin: a Southwest Oncology Group Study. Int J Urol (1996) 0.83
Genetic adaptive neural network to predict biochemical failure after radical prostatectomy: a multi-institutional study. Mol Urol (2001) 0.83
Urodynamic evaluation of incontinence in patients undergoing modified Campbell radical retropubic prostatectomy: a prospective study. J Urol (1984) 0.83
Phase II studies of recombinant human tumor necrosis factor alpha in patients with malignant disease: a summary of the Southwest Oncology Group experience. J Immunother (1991) (1991) 0.82
Use of artificial neural networks in the clinical staging of prostate cancer: implications for prostate brachytherapy. Tech Urol (2000) 0.82
Probability of prostate cancer detection based on results of a multicenter study using the AxSYM free PSA and total PSA assays. Urology (2000) 0.82
Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer. BJU Int (1999) 0.81
Therapeutic strategies for localized prostate cancer. Rev Urol (2001) 0.81
Adrenal steroid levels in castrated men with prostatic carcinoma treated with aminoglutethimide plus hydrocortisone. Cancer Res (1987) 0.81
Urinary lactic dehydrogenase and serum C-reactive protein as means of localizing the site of urinary tract infection in patients with ileal conduits. J Urol (1982) 0.81
Prostate cancer: epidemiology and screening. Rev Urol (2000) 0.81
Artificial neural network model to predict biochemical failure after radical prostatectomy. Mol Urol (2001) 0.81
Adverse reactions to the intravesical administration of doxorubicin hydrochloride: report of 6 cases. J Urol (1986) 0.80
Combined androgen blockade: the gold standard for metastatic prostate cancer. Eur Urol (1997) 0.80
Estimating the cost effectiveness of total androgen blockade with flutamide in M1 prostate cancer. Urology (1995) 0.80
Oral bropirimine immunotherapy of carcinoma in situ of the bladder: results of a phase II trial. Urology (1996) 0.80
Phase II trial of cyclophosphamide, doxorubicin, and cisplatin (CAP) versus amsacrine in patients with transitional cell carcinoma of the urinary bladder: a Southwest Oncology Group study. Cancer Treat Rep (1985) 0.80
Neurogenic pulmonary edema associated with autonomic dysreflexia. J Urol (1982) 0.79
Use of artificial neural networks in prostate cancer. Mol Urol (2001) 0.79
Doxorubicin, mitomycin C and 5-fluorouracil in the treatment of hormone refractory adenocarcinoma of the prostate: a Southwest Oncology Group study. J Urol (1993) 0.78
A phase II trial of interferon-alpha and 5-fluorouracil in patients with advanced renal cell carcinoma. A Southwest Oncology Group study. Cancer (1996) 0.78
Predictive modeling techniques in prostate cancer. Mol Urol (2001) 0.78
Phase II trial of echinomycin for the treatment of advanced renal cell carcinoma. A Southwest Oncology Group study. Invest New Drugs (1994) 0.78
Randomized clinical trial comparing balloon dilatation to transurethral resection of prostate for benign prostatic hyperplasia. Urology (1993) 0.78